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AbsTrACT
The cornea was the first human solid tissue to be 
transplanted successfully, and is now a common 
procedure in ophthalmic surgery. The grafts come from 
deceased donors. Corneal therapies are now being 
developed that rely on tissue from living-related donors. 
This presents new ethical challenges for ophthalmic 
surgeons, who have hitherto been somewhat insulated 
from debates in transplantation and donation ethics. 
This paper provides the first overview of the ethical 
considerations generated by ocular tissue donation 
from living donors and suggests how these might 
be addressed in practice. These are discussed in the 
context of a novel treatment for corneal limbal stem 
cell deficiency. This involves limbal cell grafts which are 
transplanted, either directly or after ex vivo expansion, 
onto recipient stem cell-deficient eyes. Where only one 
eye is diseased, the unaffected eye can be used as 
a source of graft tissue. Bilateral disease requires an 
allogenic donation, preferably from a genetically related 
living donor. While numerous papers have dealt with 
the theory, surgical approaches and clinical outcomes 
of limbal stem cell therapies, none has addressed the 
ethical dimensions of this form of tissue donation.
InTroduCTIon
The first successful corneal transplant was performed 
in 1905 by Eduard Zirm, using the cornea of a boy 
aged 11 years, who was due to have an eviscera-
tion. The cornea was grafted to a farm labourer 
who had been blinded by severe alkali burns.1 This 
serendipitous living donation paved the way for the 
field of corneal transplantation, which now relies 
on deceased donation. Due to the immune privilege 
of the eye, corneas are not routinely human leuco-
cyte antigen (HLA)-matched, resulting in more 
potential donors. In addition, corneas do not need 
to be retrieved from donors immediately on death, 
as is the case with other solid organs, and can be 
stored for several days after procurement.2 There is 
no upper age limit3 and donations can be retrieved 
from non-hospital environments such as hospices, 
nursing home and funeral parlours. Despite this, 
there is still a severe shortage of donor corneas 
relative to demand worldwide, with only 1 cornea 
being available for every 70 needed.4 Living-related 
donors are not considered viable sources of corneas, 
as donation would result in a blind eye. Recent 
advances in corneal treatments, such as limbal stem 
cell transplantation for limbal stem cell deficiency 
(LSCD), do, however, depend on living donors as 
we shall now explain.
In healthy people, limbal stem cells regenerate the 
corneal epithelium and prevent conjunctival cells 
from migrating over the corneal surface. After severe 
injury, typically chemical burns, chronic inflamma-
tion and certain genetic diseases, the limbal stem 
cells may be lost and the cornea becomes vascula-
rised and opaque, leading to blindness5 6 (figure 1). 
In such cases, standard corneal transplants fail 
because of the inability to maintain a healthy epithe-
lium. Limbal stem cell transplantation is designed to 
address this problem by replacing the damaged or 
lost limbal stem cells (LSC) and restoring the ocular 
surface, which in turn increases the success rates of 
subsequent sight-restoring corneal transplants.7 8 
Limbal stem cell donations only entail the removal 
of small piece of tissue from the donor’s eye. This 
is placed on the recipient’s injured eye either imme-
diately or after ex vivo expansion (figure 2). When 
the disease is unilateral, the patient can donate 
stem cells from their own healthy eye but in bilat-
eral cases the options are limited to allogeneic cell 
sources. Either deceased or living-related donors’ 
tissue may be used, but the latter is preferred as it 
has the advantage of providing a higher degree of 
histocompatibility.
These advances mean that corneal surgeons, for 
the first time, have to consider the ethical issues 
surrounding living donation that are familiar to 
other transplant specialists. Given the traditional 
dependence on deceased donation and potential 
for corneas to be retrieved many hours after death 
and preserved in banks, corneal surgeons have been 
largely insulated from transplant ethics controver-
sies. They may not, therefore, be accustomed to 
considering what the ethical norms for donation are 
or should be. They are also unlikely to be engaged 
with current ethical controversies in living dona-
tion. As the technology improves, corneal surgeons 
will have to apply, and adhere to, the ethical princi-
ples and practices that have guided other transplant 
disciplines for decades. While there is literature to 
support and promote good practices in relation to 
living donation of lung and liver lobes, kidney, bone 
marrow, umbilical cord blood and uterus, we have 
found no extant work that identifies and addresses 
ethical issues in living corneal donation. This paper 
aims to address this deficit.
HArms And benefITs
In living donation, the donor bears the risks without 
direct clinical benefit. This is unlike therapeutic 
procedures, where known risks are outweighed by 
anticipated benefits. As such, one could argue that 
all living donation contravenes the most basic prin-
ciple of medical ethics: first do no harm. Arguments 
countering this approach point to non-clinical or 
‘indirect’ benefits that family members get from 
helping each other. After all, their interests are often 
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Figure 1 Example of total limbal stem cell deficiency 
following a chemical burn. Note the opacification of the 
cornea and the presence of neovessels over 360°.
Figure 2 Different steps of a cultivated limbal stem cell 
transplantation: (A) limbal biopsy harvest of donor eye; 
(B) ex vivo cultivation of the cells; (C) transplantation of 
the compound graft onto the recipient eye; (D) result post 
cultivated limbal epithelial transplantation (CLET); (E) 
result following sight restoring penetrating keratoplasty.
intertwined, particularly in the case of parents and children. In 
the context of life-threatening conditions like liver failure, for 
example, a family member may feel that preventing the death 
of a loved one, by donating a liver lobe, is of direct benefit to 
them—it avoids (or postpones) the pain of bereavement.
It might, therefore, be argued that what counts from the 
living donors’ perspective is that, in their autonomous judge-
ment, the harms and risks to themselves are outweighed by the 
benefit to the recipient, and what counts from the perspective 
of the surgeon retrieving the tissue is that the benefit to the 
recipient should outweigh the harms and risks to the donor.9 
Before proceeding to any kind of surgery, a surgeon must be 
satisfied that there is a favourable balance of harms and bene-
fits. This is no less true in case of corneal surgery. The potential 
harm of frustrating the autonomous wishes of the donor, as well 
as concerns about the potential harms risked by the donation, 
should be taken into account.
More widely, ethical features include the burdens and costs 
of not treating potential recipients. Visual impairment and 
blindness cause considerable economic burden for both affected 
persons, their caregivers and society. These costs increase with 
the degree of visual impairment, with the mean annual expenses 
per patient estimated at US$ purchasing power parities (PPP) 
14 822– 24 180 in case of blindness, which is almost twice the 
cost for non-blind patients.10
A classic deceased-donor corneal transplant could be 
performed in an LSC-deficient eye but the prognosis is poor 
without LSCs. It may not, therefore, be a fair and prudent use of 
corneal tissue that could be used more effectively in an alternate 
recipient. Limbal stem cell transplantation aims to restore the 
limbal microenvironment and the anterior cornea: it is not a life-
saving procedure for the recipient. It may, however, significantly 
improve their quality of life by improving vision and alleviate 
symptoms, such as pain or photophobia. Living-related donors 
of stem cells are helping their family members and are helping to 
maximise the absolute number of donated corneas available, by 
reducing the demand for them.
THe ConsenT proCess
The value of respecting the donor's autonomous judgement of 
the risks and potential benefits of donation is weight-bearing in 
arguments in favour of living donation. A robust consent process 
is one way to safeguard autonomy. Corneal surgeons are expe-
rienced in gaining consent prior to conducting surgery on their 
patients. In living corneal cell donation, gaining consent for 
eye surgery entails agreement to surgery, but without the thera-
peutic purpose. There is no direct clinical benefit for the donor; 
instead, the clinical benefits—if successful—will accrue to the 
recipient. Its success will, however, bring other sorts of benefits 
to the donor, such as the family member’s visual rehabilitation.
This process also needs to reflect the fact that successful living 
donation requires a tandem consent process: both donor and 
recipient need to agree. In the case of directed living donation, 
where tissue passes between prespecified individuals, the identity 
of those individuals is a key factor. So, for example, one might 
imagine a parent who is willing to receive limbal tissue, but not 
from their own adult child because they are unwilling to agree to 
their offspring taking any risk to his/her eyesight, however small, 
for their benefit. Equally, one can imagine a donor who might 
be willing to provide limbal tissue for some family members, but 
not others.
Capacity
Capacity may fluctuate and individuals who have the capacity 
to make more simple decisions might not necessarily be able to 
make more complex ones. To have capacity, an individual must 
be able understand the information necessary to make a deci-
sion, retain this information, be able to deliberate and be able 
to communicate the outcome of his/her deliberations. There is 
often a legal presumption in favour of capacity in the case of 
adults/individuals of legal age to consent to or refuse medical 
interventions. This presumption does not, however, permit prac-
titioners to abrogate responsibility for assessing capacity of indi-
viduals who have reached the age of majority (or other relevant 
legal threshold). If there is uncertainty about capacity, this may 
indicate a need to involve other professionals or to slow down 
the process and greatly simplify the information provided. The 
presumption in favour of capacity serves as a reminder to practi-
tioners that an individual can be rendered incompetent by poor 
communications skills, such as the use of technical terms, visible 
impatience and inflexibility in their approach to how complex 
information is transmitted. Capacity is clearly interconnected, 
therefore, with information: both recipients and donors need 
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Figure 3 Flow diagram of the suggested consent process.
adequate knowledge and comprehension of the risks, bene-
fits, alternatives and outcomes to provide adequate informed 
consent.
Information
As a minimum, the information provided to both donor and 
recipient should include a description of, and discussion about, 
the diagnosis and prognosis, the procedure, overview of the 
purpose and effectiveness of the intervention, any contraindi-
cations, medical uncertainties, side effects and risks, necessary 
aftercare, potential financial and other social consequences and 
similar, relevantly detailed information about other available 
alternatives, including doing nothing.
In the case of limbal tissue donation specifically, the aim is 
to restore the ocular surface and eventually reverse the recipi-
ent’s corneal blindness by using the donated limbal tissue. The 
donation or ‘biopsy procedure’ itself only takes a few minutes 
and requires minimal aftercare. That being said, patients often 
feel more anxious about eye surgery specifically than other 
surgical interventions. Indeed, sight has been considered the 
most important of the five senses.11 The risks related to tissue 
removal should be discussed with the potential donor. While 
these are less significant than solid organ donation, the special 
nature of the eye should still be taken into account. Surgical 
risks in conjunctival limbal donation include the development 
of LSCD in the donor eye, pseudopterygium, filamentary kera-
titis and microperforation during surgery.12–14 Modern stem cells 
techniques were specifically developed to use smaller biopsies, 
which has significantly reduced the risks to the donor eye. It 
also offers the possibility of taking a second biopsy, if needed; 
however, in this case the process of gaining consent would need 
to be repeated. The consequences of a relative deciding not to 
donate are not life-threatening for the potential recipient, but 
they may have to wait longer for a suitable deceased donation, 
or ultimately their LSCD may not be cured, both of which can 
have an impact on their quality of life.
For the potential recipient, the surgical risks related to 
receiving a stem cell donation are less than those for routine 
corneal transplants. The culture protocols of the CLET tech-
nique have, however, introduced new issues. There is the poten-
tial for contamination with infectious agents related to the use 
of animal and/or human tissue.15 The use of allogeneic donor 
cells includes the risk of rejection, although HLA-compatible 
grafts may improve survival. Because this is a tandem process, 
the donor needs to be provided with clear information about 
the risks and consequences of transplant failure for the recip-
ient, and the recipient needs to understand the risks and conse-
quences for the potential donor. Information provision for each 
party needs to be equally rigorous.
Voluntariness
The potential for coercion to be brought to bear on donors 
outside of the clinic environment is a common feature of all 
types of living tissue donation. Obviously, a decision is not an 
autonomous one if it is made as a result of coercion, and the 
line between coercion and reasonable persuasion is a fine one.16 
Family pressures, emotions or other external influences may play 
a role in manipulating the donor’s voluntary choices or might 
otherwise cause unnecessary anxiety or distress. Deciding against 
donation may provoke family hostility or generate feelings of 
guilt.17 Undue family influence may not be immediately obvious. 
However, ophthalmologists tasked with screening potential 
donors have an obligation to engage in detailed, private conver-
sations to rule out the possibility of any coercion.18
In the case of living kidney donation, it is common—after an 
initial willingness to donate has been established—for the care 
of donors, including that related to consent, to be passed to a 
team that is independent of the potential recipient. This avoids 
the possibility of coercion in the clinic, or any potential appear-
ance of coercion. The living donation process is new in corneal 
transplant surgery and affects relatively few patients. It may not be 
economically viable for clinics to establish parallel recipient/donor 
teams until numbers increase substantially. It is also likely that in 
smaller centres only one corneal surgeon will be involved, which 
will also make it logistically and economically difficult to estab-
lish a dedicated, independent team of practitioners (including a 
dedicated coordinator and counsellor) to serve living donors. In 
large centres this may be feasible and should therefore be consid-
ered. All centres, however small, which recruit living donors must 
have a transparent and robust consent process. Most centres in 
high-income countries should be able to provide an independent 
(of the recipient) ophthalmic specialist to discuss the process with 
the donor, including any fears, concerns or reservations. Figure 3 
illustrates this suggested consent process. Additional training and 
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support in the ethical dimensions of providing care to living donors 
should be included as part of any training packages devised for 
new corneal surgery that depends on them, and additional training 
should also be provided to any non-participating, independent 
ophthalmic specialists who will be used to support the donors.
All processes should comply with existing legal framework on 
tissue donation, such as the Tissues and Cell Directive (2004/23/
EC) for Europe, which defines safety and quality standards for 
tissues and cell donation.19
Payment for tissues donation is not permitted in the European 
Union, and other jurisdictions partly because it is regarded as 
a potentially coercive inducement. The Declaration of Istanbul 
also prohibits all forms of transplant tourism and the trafficking 
of donors or their tissue across jurisdictional borders.20 This 
Declaration is endorsed by WHO and is implemented as one 
of the 11 Guiding Principles on Human Cell, Tissue and Organ 
Transplantation.21
decision
Both the donor and the recipient should be given time to consider 
the information provided, including seeking the advice and 
counsel of others they trust. This is both an ethical requirement 
and a pragmatic one. It is sometimes assumed that people will feel 
rushed into consenting, but other people, if rushed, may be more 
inclined to refuse since this maintains the status quo. Although 
it is not often conceived of this way, such a rushed refusal would 
also be less than voluntary and therefore potentially as uneth-
ical as a rushed consent. People who agree in haste may also be 
more inclined to change their minds, or not to have grasped the 
gravity of the commitments involved. A change of mind may 
create disappointment and resentment within the family and 
also waste valuable clinical time and money with unnecessary 
workup procedures. Failure to fully understand what is required 
may result in less than optimal self-care following the procedure. 
The expectations of the donor and recipient, as well as their 
continued agreement, should, however, always be reviewed by 
the person carrying out the intervention immediately prior to its 
being performed.
donor unwillingness to consent
A donor who expresses reluctance in a private conversation 
needs to be managed sensitively, including ensuring that the 
response from the healthcare practitioners is not itself coer-
cive (eg, expressing disapproval or disappointment verbally 
or non-verbally). Moreover, donors are as entitled to enjoy a 
confidential relationship with their doctor as recipients. As we 
are recommending that the donor is seen by an independent 
ophthalmologist, this specialist will need to discuss with the 
potential donor whether the reasons for their reluctance can be 
shared with the recipient team and ultimately the recipient. If 
they are not willing to discuss their reluctance with the potential 
recipient and are unwilling to give the practitioners permission 
to disclose the information, this presents a difficulty. The poten-
tial recipient may expect to be given a reason as to why the dona-
tion cannot go ahead.
One solution is for staff to follow George Canguilhem’s distinc-
tion between ‘truth’ as ‘quality by which things appear such as they 
are’, versus, ‘true’ (vrai), as used in Latin in the sense of ‘real’ and 
‘regular’ or ‘correct'.22 Here, a distinction is being drawn between 
disclosure of the whole truth and being generally honest, while 
disclosing less detail. A donor could, for instance, be declared as 
‘unsuitable’ since being reluctant to consent would render them 
ineligible to proceed. The decision about how to proceed in 
circumstances such as these will depend on available alternatives 
(eg, other living-related donors or deceased donation). On the 
whole, however, it might be best to counsel openness and trans-
parency wherever possible, especially given the importance of 
maintaining relationships of trust and confidence in dealings with 
these two individuals and between the professional as a whole and 
the public. These sorts of issues are not unusual in circumstances 
where practitioners have dealings with different family members, 
such as genetics and general practice.
donor screening and dealing with unanticipated, adverse 
results
Infectious diseases such syphilis, hepatitis and HIV must be ruled 
out to avoid transmitting these to the recipient. HLA-matching 
may also be necessary to reduce the risk of rejection. Informa-
tion about such tests should be clearly explained to the donor 
prior to screening, including the right to receive the confirmed 
results. Ethical issues arise when positive test results (eg, positive 
serology for HIV) are unexpected or where previously undis-
closed non-paternity is revealed. Either may render the donor 
unsuitable. We might suppose that someone who has agreed 
to a test has agreed to receive the results. Although the term 
‘screening’ is used in this context, it is not quite the same as its 
use in relation to population screening. The donor is not being 
tested as an asymptomatic member of an ‘at-risk’ population, 
where the burdens and benefits have been carefully calculated as 
part of a conventional screening programme, and where treat-
ment has to be available for any conditions detected.23 24 Nor are 
they being tested because they have symptoms that need inves-
tigation and treatment, conducted within a regular healthcare 
context. In these latter contexts, those conducting the tests will 
have knowledge and expertise in relation to the conditions for 
which donors are being tested. This may not be the case among 
corneal surgeons, and protocols will need to be developed within 
clinics to ensure the compassionate management and referral on 
for treatment of those who are given adverse, potentially stig-
matising results.
Ethical issues in relation to the obligations to disclose serious 
infectious disease to others who may be at risk of infection could 
be passed on with a referral, leaving it to those with more exper-
tise on the receiving team to offer advice and counselling. This 
solution assumes, however, that the potential donor will agree to 
a referral, so plans need to be placed for how to manage anyone 
who refuses. In addition, certain infectious diseases are notifiable 
to the relevant authorities for disease control and surveillance. 
Information about these legal obligations needs to be provided 
as part of the consent process.
The issue of how to respond to suspected misattributed pater-
nity is widely discussed in the transplant, genetics and in other 
bioethics literature.25–27 Clinics that offer donation schemes 
need to counsel individuals ahead of testing about this possibility 
and include information about any policies in place regarding 
(non)disclosure. In some cases, it may be appropriate to offer the 
donor the option of not receiving results. This is consistent with 
how other potential, unexpected results are managed where 
no treatment is available and/or there is no risk to others. The 
choice to opt-out of receiving results in other circumstances will 
inevitably generate difficult ethical issues and is best avoided. If 
necessary, an alternative donor could be found or the plans for 
transplant in the case of this potential recipient changed.
Infection risk is usually initially assessed by administering 
a questionnaire to the potential donor, covering ‘Creutzfeldt-
Jakob Disease’ and rabies among others. If the donor knows that 
they are HIV positive, for example, they can then be excluded 
straight away. Potential donors should not be asked to complete 
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such questionnaires, either verbally or in writing, while they 
are in a public area, given that these checklists include sensitive 
information. A copy of the form should be provided to them 
during the initial consultation to be completed in private and the 
potential recipient should also not be present. These measures 
protect the privacy of the donor and may encourage greater 
honesty in the questionnaire’s completion.
ConClusIon
It is imperative that all clinicians involved with any form of 
(living-related) tissue donation engage with the related ethical 
issues. For corneal surgeons, this field is relatively new and there 
are currently no specific professional guidelines dealing with these 
practices. In this paper, we have set out some of the important 
ethical considerations and considered how these might be managed 
in practice, with the aim of provoking discussion and improving 
provision of local and specialty policies and guidelines to promote 
good practice in this emerging area of living donation.
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